These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 11152294)

  • 1. Theoretical conformational analysis of six arginine vasopressin analogs with the L-naphthylalanine in position 3.
    Slusarz R; Kaźmierkiewicz R; Lammek B
    J Pept Res; 2000 Dec; 56(6):352-9. PubMed ID: 11152294
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Theoretical conformational analysis of three vasopressin antagonists with a modified cyclohexyl ring in the first thioacid residue.
    Kaźmierkiewicz R; Liwo A; Lammek B
    Int J Pept Protein Res; 1995 May; 45(5):451-8. PubMed ID: 7591484
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Influence of L-naphthylalanine in position 3 of AVP and its analogues on their pharmacological properties.
    Lammek B; Czaja M; Derdowska I; Rekowski P; Trzeciak HI; Sikora P; Szkróbka W; Stojko R; Kupryszewski G
    J Pept Res; 1997 Mar; 49(3):261-8. PubMed ID: 9151259
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Exploration of the conformational space of oxytocin and arginine-vasopressin using the electrostatically driven Monte Carlo and molecular dynamics methods.
    Liwo A; Tempczyk A; Ołdziej S; Shenderovich MD; Hruby VJ; Talluri S; Ciarkowski J; Kasprzykowski F; Lankiewicz L; Grzonka Z
    Biopolymers; 1996 Feb; 38(2):157-75. PubMed ID: 8589250
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An investigation of position 3 in arginine vasopressin with aliphatic, aromatic, conformationally-restricted, polar and charged amino acids.
    Stoev S; Cheng LL; Olma A; Klis WA; Manning M; Sawyer WH; Wo NC; Chan WY
    J Pept Sci; 1999 Mar; 5(3):141-53. PubMed ID: 10323558
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Analogues of arginine vasopressin modified in position 2 or 3 with naphthylalanine: selective antagonists of oxytocin in-vitro.
    Sobocińska M; Lempicka E; Konieczna E; Derdowska I; Lammek B; Melhem S; Kozik W; Janecka J; Janecki M; Trzeciak HI
    J Pharm Pharmacol; 2000 Sep; 52(9):1105-12. PubMed ID: 11045891
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Highly potent antidiuretic antagonists: conformational studies of vasopressin analogues modified with 1-naphthylalanine enantiomers at position 2.
    Lubecka EA; Ciarkowski J; Prahl A; Sikorska E
    Chem Biol Drug Des; 2012 Jun; 79(6):1033-42. PubMed ID: 22321057
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Surprising pharmacological activity of analogues designed by substitution of position 3 in arginine vasopressin (AVP) and 8-D-arginine vasopressin with L-2-napthylalanine.
    Lammek B; Konieczna E; Trzeciak HI; Kozłowski A; Szymkowiak J; Stojko R; Kupryszewski G
    J Pharm Pharmacol; 1996 Mar; 48(3):316-9. PubMed ID: 8737061
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Conformational analysis of [Cpp1, Sar7, Arg8] vasopressin by 1H-NMR spectroscopy and molecular mechanics calculations.
    Shenderovich MD; Kasprzykowski F; Liwo A; Sekacis I; Saulitis J; Nikiforovich GV
    Int J Pept Protein Res; 1991 Dec; 38(6):528-38. PubMed ID: 1819587
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Conformational studies of stereoisomeric 14-membered cyclic enkephalin analogues containing 1-naphthylalanine at the fourth position: chirality effect of leucine at the fifth position on biological activity and receptor selectivity.
    Yamazaki T; Said-Nejad OE; Schiller PW; Goodman M
    Biopolymers; 1991 Jun; 31(7):877-98. PubMed ID: 1655089
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Arginine vasopressin and its analogues--the influence of position 2 modification with 3,3-diphenylalanine enantiomers. Highly potent V2 agonists.
    Kwiatkowska A; Sobolewski D; Prahl A; Borovicková L; Slaninová J; Lammek B
    Eur J Med Chem; 2009 Jul; 44(7):2862-67. PubMed ID: 19418631
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An exploration of the effects of L- and D-tetrahydroisoquinoline-3-carboxylic acid substitutions at positions 2, 3 and 7 in cyclic and linear antagonists of vasopressin and oxytocin and at position 3 in arginine vasopressin.
    Manning M; Cheng LL; Stoev S; Bankowski K; Przybyiski J; Klis WA; Sawyer WH; Wo NC; Chan WY
    J Pept Sci; 1995; 1(1):66-79. PubMed ID: 9222985
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Position three in vasopressin antagonist tolerates conformationally restricted and aromatic amino acid substitutions: a striking contrast with vasopressin agonists.
    Manning M; Cheng LL; Stoev S; Klis W; Nawrocka E; Olma A; Sawyer WH; Wo NC; Chan WY
    J Pept Sci; 1997; 3(1):31-46. PubMed ID: 9230469
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Design and synthesis of the first selective agonists for the rat vasopressin V(1b) receptor: based on modifications of deamino-[Cys1]arginine vasopressin at positions 4 and 8.
    Pena A; Murat B; Trueba M; Ventura MA; Wo NC; Szeto HH; Cheng LL; Stoev S; Guillon G; Manning M
    J Med Chem; 2007 Feb; 50(4):835-47. PubMed ID: 17300166
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Probing the V1a vasopressin receptor binding site with pyroglutamate-substituted linear antagonists.
    Howl J; Yarwood NJ; Stock D; Wheatley M
    Neuropeptides; 1996 Feb; 30(1):73-9. PubMed ID: 8868303
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Influence of bulky 3,3'-diphenylalanine enantiomers replacing position 2 of AVP analogues on their conformations: NMR and molecular modeling studies.
    Sikorska E; Kwiatkowska A; Sobolewski D; Slusarz R; Slusarz MJ
    Eur J Med Chem; 2010 Sep; 45(9):4065-73. PubMed ID: 20580135
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synthesis and structure-activity investigation of novel vasopressin hypotensive peptide agonists.
    Manning M; Stoev S; Cheng LL; Wo NC; Chan WY
    J Pept Sci; 1999 Nov; 5(11):472-90. PubMed ID: 10587312
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular mechanics calculations on deaminooxytocin and on deamino-arginine-vasopressin and its analogues.
    Liwo A; Tempczyk A; Grzonka Z
    J Comput Aided Mol Des; 1989 Jan; 2(4):281-309. PubMed ID: 2715790
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Structure--function studies of vasopressin analogues with D-3 pyridyl-alanine in position 2.
    Sobocinska M; Derdowska I; Schwartz J; Kupryszewski G
    Peptides; 1995; 16(3):389-93. PubMed ID: 7651889
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Structure of pressinoic acid: the cyclic moiety of vasopressin.
    Langs DA; Smith GD; Stezowski JJ; Hughes RE
    Science; 1986 Jun; 232(4755):1240-2. PubMed ID: 3704648
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.